Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination.
Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination.
复制标题
抗SARS-COV-2受体结合结构域的血清阳性和血清效率医疗保健工人的总抗体反应正在接受COVID-19 MRNA BNT162B2疫苗接种。
DOI：
10.3390/diagnostics11050832
复制
发表时间：
2021-05-04
期刊：
影响因子：
--
通讯作者：
Lippi G
中科院分区：
文献类型：
--
作者：
Salvagno GL;Henry BM;di Piazza G;Pighi L;De Nitto S;Bragantini D;Gianfilippi GL;Lippi G
背景：本研究监测了大量接受 mRNA COVID-19 疫苗接种的医护人员中的总抗 SARS-CoV-2（严重急性呼吸综合征冠状病毒 2）RBD（受体结合域）抗体水平。方法。研究人群包括 Peschiera del Garda（意大利维罗纳）Pederzoli 医院的员工，他们自愿接种了两剂 COVID-19 mRNA BNT162b2（Comirnaty；辉瑞公司）。在第一次疫苗接种前、21 天（第二次疫苗接种前）和 50 天后抽取静脉血。在 Roche Cobas 6000（罗氏诊断）上使用 Roche Elecsys 抗 SARS-CoV-2 S 总抗体评估体液反应。结果：最终研究人群包括 925 名受试者（平均年龄 44 ± 13 岁；457 名女性），其中 206 名（22.3%）抗 SARS-CoV-2 基线血清呈阳性。首次接种疫苗 21 天后，血清阳性个体的总抗 SARS-CoV-2 RBD 抗体水平比血清阴性个体高出约 3 个数量级（11782 vs. 42 U/mL；p < 0.001）。在基线血清阴性受试者中，第二剂疫苗接种后，总抗 SARS-CoV-2 RBD 抗体水平进一步增加了 30 倍以上，而在基线血清阳性受试者中，这种增加仅约 1.3 倍。在多变量分析中，在基线血清阴性受试者中，总抗 SARS-CoV-2 RBD 抗体水平与两次疫苗接种后的年龄和第二次疫苗接种后的男性性别呈负相关，而基线抗体值显着预测基线血清阳性接受者在两次疫苗接种后的免疫反应。结论：基线血清阴性和血清阳性受试者的 mRNA COVID-19 疫苗后免疫反应存在显着差异，这似乎取决于血清阴性受试者的年龄和性别，以及血清阳性患者的基线抗 SARS-CoV-2 抗体水平。
Background: This study monitored total anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) RBD (receptor-binding domain) antibodies levels in a large population of healthcare workers undergoing mRNA COVID-19 vaccination. Methods. The study population consisted of employees of Pederzoli Hospital of Peschiera del Garda (Verona, Italy), who underwent voluntary vaccination with two doses of COVID-19 mRNA BNT162b2 (Comirnaty; Pfizer Inc). Venous blood was drawn immediately before the first vaccine dose, as well as 21 days (immediately before second vaccine dose) and 50 days afterwards. Humoral response was assessed with Roche Elecsys Anti-SARS-CoV-2 S total antibodies, on Roche Cobas 6000 (Roche Diagnostics). Results: The final study population consisted of 925 subjects (mean age, 44 ± 13 years; 457 women), 206 (22.3%) anti-SARS-CoV-2 baseline seropositive. The increase of total anti-SARS-CoV-2 RBD antibodies levels 21 days after the first vaccine dose was ~3 orders of magnitude higher in seropositive than in seronegative individuals (11782 vs. 42 U/mL; p < 0.001). Total anti-SARS-CoV-2 RBD antibodies levels further increased by over 30-fold after the second vaccine dose in baseline seronegative subjects, while such increase was only ~1.3-fold in baseline seropositive subjects. In multivariate analysis, total anti-SARS-CoV-2 RBD antibodies level was inversely associated with age after both vaccine doses and male sex after the second vaccine dose in baseline seronegative subjects, while baseline antibodies value significantly predicted immune response after both vaccine doses in baseline seropositive recipients. Conclusion: Significant difference exists in post-mRNA COVID-19 vaccine immune response in baseline seronegative and seropositive subjects, which seems dependent on age and sex in seronegative subjects, as well as on baseline anti-SARS-CoV-2 antibodies level in seropositive patients.
登录
查看更多内容
影响因子：
82.9
作者：
Levine-Tiefenbrun, Matan;Yelin, Idan;Kishony, Roy
通讯作者：
Kishony, Roy
影响因子：
82.9
作者：
Ebinger JE;Fert-Bober J;Printsev I;Wu M;Sun N;Prostko JC;Frias EC;Stewart JL;Van Eyk JE;Braun JG;Cheng S;Sobhani K
通讯作者：
Sobhani K
DOI：
10.3390/diagnostics11030426
发表时间：
2021-03-03
期刊：
Diagnostics (Basel, Switzerland)
影响因子：
--
作者：
Dörschug A;Frickmann H;Schwanbeck J;Yilmaz E;Mese K;Hahn A;Groß U;Zautner AE
通讯作者：
Zautner AE
影响因子：
6.8
作者：
Danese, Elisa;Montagnana, Martina;Lippi, Giuseppe
通讯作者：
Lippi, Giuseppe
影响因子：
6.8
作者：
Bohn, Mary Kathryn;Loh, Tze Ping;Adeli, Khosrow
通讯作者：
Adeli, Khosrow